Cao, Q., Hajosch, A., Kast, R. E., Loehmann, C., Hlavac, M., Fischer-Posovszky, P., Strobel, H., Westhoff, M.-A., Siegelin, M. D., Wirtz, C. R., Halatsch, M.-E., & Karpel-Massler, G. (2024). Tumor Treating Fields (TTFields) combined with the drug repurposing approach CUSP9v3 induce metabolic reprogramming and synergistic anti-glioblastoma activity in vitro. British Journal of Cancer, 130(8), 1365–1376. https://doi.org/10.1038/s41416-024-02608-8

O’Mahony, D. G., Ramus, S. J., Southey, M. C., Meagher, N. S., Hadjisavvas, A., John, E. M., Hamann, U., Imyanitov, E. N., Andrulis, I. L., Sharma, P., Daly, M. B., Hake, C. R., Weitzel, J. N., Jakubowska, A., Godwin, A. K., Arason, A., Bane, A., Simard, J., … Soucy, P. (2023). Ovarian cancer pathology characteristics as predictors of variant pathogenicity in BRCA1 and BRCA2. British Journal of Cancer, 128(12), 2283–2294. https://doi.org/10.1038/s41416-023-02263-5

Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J. J., Calvo, E., Carvajal, R. D., Nyakas, M., Gonzalez-Maffe, J., Zhu, X., Shirley, M. D., Ramkumar, T., Fessehatsion, A., Burks, H. E., Yerramilli-Rao, P., & Kapiteijn, E. (2023). A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma. British Journal of Cancer, 128(6), 1040–1051. https://doi.org/10.1038/s41416-022-02133-6

Jung, S., Armstrong, E., Wei, A. Z., Ye, F., Lee, A., Carlino, M. S., Sullivan, R. J., Carvajal, R. D., Shoushtari, A. N., & Johnson, D. B. (2022). Clinical and genomic correlates of imatinib response in melanomas with KIT alterations. British Journal of Cancer, 127(9), 1726–1732. https://doi.org/10.1038/s41416-022-01942-z

Shao, Y.-Y., Chen, P.-S., Lin, L.-I., Lee, B.-S., Ling, A., Cheng, A.-L., Hsu, C., & Ou, D.-L. (2022). Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. British Journal of Cancer, 126(12), 1806–1814. https://doi.org/10.1038/s41416-022-01759-w